Loading
Giving all three chemotherapy drugs at once instead of two shrank more tumours and delayed progression, at the cost of more side effects.
TRIBE randomised 508 patients with untreated metastatic colorectal cancer to FOLFIRI plus bevacizumab or FOLFOXIRI plus bevacizumab, up to twelve cycles followed by fluorouracil and bevacizumab maintenance. Median progression-free survival was 12.1 against 9.7 months (hazard ratio 0.75, 95% CI 0.62 to 0.90, p=0.003) and the objective response rate 65 against 53 percent (p=0.006). Overall survival was longer but not significantly so in the primary report (31.0 against 25.8 months, hazard ratio 0.79, p=0.054). Grade 3 or 4 neurotoxicity, stomatitis, diarrhoea and neutropenia were all more common with the triplet. TRIBE is why FOLFOXIRI plus bevacizumab is chosen when tumour shrinkage matters most: in BRAF-mutant disease, in young fit patients and when liver metastases might be made resectable.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
508 randomised.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | FOLFOXIRI plus bevacizumab | - | 12.1 months | 0.75 (0.62 to 0.9) | 0.003 | link |
| FOLFIRI plus bevacizumab | - | 9.7 months | ||||
| Overall survival | FOLFOXIRI plus bevacizumab | - | 31 months | 0.79 | 0.054 | link |
| FOLFIRI plus bevacizumab | - | 25.8 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Oxaliplatin, VEGF / VEGFR.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads).
Shares Irinotecan (and liposomal irinotecan), VEGF / VEGFR, Fluorouracil (5-FU), Anti-angiogenic therapy.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads).
Shares FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Bevacizumab.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads), Bevacizumab.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Fluorouracil (5-FU).
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Topoisomerase-I inhibitors (and ADC payloads), Bevacizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/